DD · 10-Q · 2026Q3 · Full report
Aramids Divestiture
DuPont de Nemours, Inc. · 2026-11-03 · Importance 59 · Surprise 60 · No source text
DuPont completed the sale of its Aramids business to Arclin on April 1, 2026. Consideration included approximately $1.2 billion of pretax cash proceeds, subject to customary adjustments, a $300 million note receivable and a $325 million non-controlling equity interest in Arclin. The divested business is presented as discontinued operations, including in comparative periods.
Key facts
- On April 1, 2026, DuPont completed the Aramids Divestiture to Arclin for approximately $1.2 billion in pre-tax cash proceeds, a $300 million note receivable, and equity consideration valued at $325 million. source
- DuPont's Aramids business results are reflected as discontinued operations, along with comparative periods. source
- Continuing-operations cash provided by investing activities was $920 million in the first nine months of 2026, compared with $303 million used in 2025, primarily due to Aramids Divestiture proceeds. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | realized | +5.8% | On April 1, 2026, DuPont completed the Aramids Divestiture to Arclin for approximately $1.2 billion in pre-tax cash proceeds, a $300… |
| assets | positive | realized | +3.0% | On April 1, 2026, DuPont completed the Aramids Divestiture to Arclin for approximately $1.2 billion in pre-tax cash proceeds, a $300… |